Disclosure: Drs Cady and Martin have received research grants and honoraria from Merck & Co., Inc. Dr Mauskop has received honoraria from Merck & Co., Inc. Mr Rodgers, Ms Ramsey, and Drs Hustad and Skobieranda are employed by Merck & Co., Inc. and may own stock options in the company.
Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies
Article first published online: 6 AUG 2007
Volume 27, Issue 9, pages 1055–1060, September 2007
How to Cite
Cady, R., Martin, V., Mauskop, A., Rodgers, A., Hustad, C., Ramsey, K. and Skobieranda, F. (2007), Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia, 27: 1055–1060. doi: 10.1111/j.1468-2982.2007.01391.x
- Issue published online: 6 AUG 2007
- Article first published online: 6 AUG 2007
- Received 8 March 2007, accepted 18 April 2007
- Cutaneous allodynia;
The presence of cutaneous allodynia may predict response to triptans. Identical randomized double-blind studies were conducted comparing the efficacy of rizatriptan 10 mg or placebo administered within 1 h of headache onset, while pain was mild. The primary endpoint was freedom from pain at 2 h. Presence of symptoms suggesting cutaneous sensitivity (SCS) at baseline and at 2 h post-treatment was recorded. Before treatment, 29% of rizatriptan patients and 22% of placebo patients reported SCS. At 2 h, the percentage of patients with SCS was significantly decreased with rizatriptan. The presence of SCS pre-treatment was not predictive of response to rizatriptan. Most patients with SCS at 2 h were non-responders. Early treatment with rizatriptan significantly reduced the percentage of patients with SCS at 2 h. The presence of SCS at baseline did not predict pain-free response, but presence of SCS at 2 h correlated with lack of a 2-h pain-free response.